{"log_id": 2669453695757251309, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 4e-06, "average": 0.998379, "min": 0.994778}, "location": {"width": 97, "top": 206, "height": 25, "left": 236}, "words": "药理毒理"}, {"probability": {"variance": 2e-06, "average": 0.99909, "min": 0.995309}, "location": {"width": 790, "top": 243, "height": 33, "left": 223}, "words": "伊达比星属于细胞毒药物,是一种DNA嵌入剂,作用于拓扑异构酶,从而抑制核"}, {"probability": {"variance": 1.7e-05, "average": 0.996151, "min": 0.990279}, "location": {"width": 67, "top": 294, "height": 24, "left": 224}, "words": "酸合成"}, {"probability": {"variance": 2e-06, "average": 0.999312, "min": 0.992849}, "location": {"width": 739, "top": 329, "height": 35, "left": 225}, "words": "该化合物具有高亲脂性,与多柔比星和柔红霉素相比,细胞对药物的摄入增加"}, {"probability": {"variance": 1e-06, "average": 0.999281, "min": 0.995466}, "location": {"width": 781, "top": 371, "height": 36, "left": 225}, "words": "与柔红霉素相比,伊达比星具有更广的抗肿瘤谱,静脉或口服用药对鼠白血病和淋"}, {"probability": {"variance": 7e-06, "average": 0.998555, "min": 0.993378}, "location": {"width": 112, "top": 422, "height": 26, "left": 223}, "words": "巴瘤更有效"}, {"probability": {"variance": 0, "average": 0.999424, "min": 0.999123}, "location": {"width": 89, "top": 508, "height": 27, "left": 225}, "words": "体外试验"}, {"probability": {"variance": 5e-06, "average": 0.99874, "min": 0.991052}, "location": {"width": 740, "top": 540, "height": 37, "left": 268}, "words": "人和鼠的体外实验表明,与多柔比星和柔红霉素相比,蒽环类耐药细胞对伊达"}, {"probability": {"variance": 1e-06, "average": 0.999176, "min": 0.997161}, "location": {"width": 328, "top": 588, "height": 30, "left": 226}, "words": "比星显示出较低程度的交叉耐药性"}, {"probability": {"variance": 4.1e-05, "average": 0.99779, "min": 0.963447}, "location": {"width": 721, "top": 623, "height": 38, "left": 268}, "words": "动物心脏毒性研究提示伊达比星比多柔比星和柔红霉素具有更高的治疗指数"}, {"probability": {"variance": 0, "average": 0.999355, "min": 0.997669}, "location": {"width": 783, "top": 667, "height": 37, "left": 227}, "words": "其主要代谢产物伊达比星醇在体内和体外的试验动物模型中均显示出良好的抗肿瘤"}, {"probability": {"variance": 0, "average": 0.999368, "min": 0.997821}, "location": {"width": 719, "top": 709, "height": 38, "left": 226}, "words": "活性。在大鼠实验中,伊达比星醇的心脏毒性明显低于相同剂量的伊达比星"}, {"probability": {"variance": 4e-06, "average": 0.998157, "min": 0.993979}, "location": {"width": 178, "top": 800, "height": 35, "left": 228}, "words": "临床前安全性数据"}, {"probability": {"variance": 0.004086, "average": 0.985997, "min": 0.63079}, "location": {"width": 712, "top": 832, "height": 44, "left": 274}, "words": "口服给药比静脉给药毒性约低三倍,且口服给药时胃肠道毒性并没有增加"}, {"probability": {"variance": 2e-05, "average": 0.99743, "min": 0.981975}, "location": {"width": 741, "top": 889, "height": 37, "left": 273}, "words": "口服给药与静脉给药或其他蒽环类药物相比,具有相同的毒性作用靶器官血"}, {"probability": {"variance": 0.003665, "average": 0.979265, "min": 0.714441}, "location": {"width": 783, "top": 930, "height": 40, "left": 230}, "words": "液淋巴系统和免疫系统、胃肠道、心脏、肝脏、肾脏、睾丸入。当静脉给药时,已"}, {"probability": {"variance": 0.021219, "average": 0.689353, "min": 0.543686}, "location": {"width": 85, "top": 954, "height": 28, "left": 895}, "words": "日性"}, {"probability": {"variance": 2.9e-05, "average": 0.998071, "min": 0.970524}, "location": {"width": 594, "top": 976, "height": 38, "left": 232}, "words": "证明肝脏和肾脏对毒性更加敏感,胃肠道和睾丸的毒性则相同。"}, {"probability": {"variance": 7e-05, "average": 0.965396, "min": 0.957038}, "location": {"width": 34, "top": 981, "height": 28, "left": 893}, "words": "3)"}, {"probability": {"variance": 7.2e-05, "average": 0.99801, "min": 0.950301}, "location": {"width": 715, "top": 1018, "height": 36, "left": 279}, "words": "与其他蒽环类药物一样,即便是口服给药,盐酸伊达比星仍被认为具有致突"}, {"probability": {"variance": 6e-06, "average": 0.998432, "min": 0.992425}, "location": {"width": 241, "top": 1067, "height": 31, "left": 233}, "words": "变、致畸和潜在的致癌性"}, {"probability": {"variance": 0, "average": 0.999761, "min": 0.999405}, "location": {"width": 118, "top": 1154, "height": 27, "left": 239}, "words": "药代动力学"}, {"probability": {"variance": 0.001022, "average": 0.992726, "min": 0.812871}, "location": {"width": 708, "top": 1185, "height": 40, "left": 277}, "words": "肝肾功能正常的患者口服给药后伊达比星被快速吸收,达峰时间为2-4小"}, {"probability": {"variance": 0.001463, "average": 0.992033, "min": 0.763026}, "location": {"width": 773, "top": 1228, "height": 41, "left": 234}, "words": "时,并从体循环中清除,其终末血浆半衰期在10-35小时之间,大部分药物经代"}, {"probability": {"variance": 0.000107, "average": 0.996362, "min": 0.936591}, "location": {"width": 788, "top": 1271, "height": 40, "left": 234}, "words": "谢生成活性代谢产物伊达比星醇,而该代谢产物的清除更慢,血浆半衰期在33-60"}, {"probability": {"variance": 0.00071, "average": 0.994673, "min": 0.83518}, "location": {"width": 771, "top": 1315, "height": 38, "left": 237}, "words": "小时之间。绝大部分药物是以伊达比星醇的形式经胆汁排出体外,1-2%的原形药"}, {"probability": {"variance": 2.4e-05, "average": 0.997941, "min": 0.972837}, "location": {"width": 767, "top": 1356, "height": 40, "left": 238}, "words": "物,最多4.6%的伊达比星醇经尿液排出。伊达比星的生物利用度按原形药物计为"}, {"probability": {"variance": 0.000462, "average": 0.992253, "min": 0.884915}, "location": {"width": 625, "top": 1402, "height": 36, "left": 282}, "words": "39%,而当按它的活性代谢产物伊达比星醇计算时,则较高(29-58"}, {"probability": {"variance": 5.9e-05, "average": 0.994313, "min": 0.983419}, "location": {"width": 67, "top": 1402, "height": 24, "left": 954}, "words": "在按药"}, {"probability": {"variance": 1.6e-05, "average": 0.997726, "min": 0.982139}, "location": {"width": 440, "top": 1446, "height": 34, "left": 239}, "words": "理学反应计算时,其有效生物利用度接近35%"}, {"probability": {"variance": 0.000219, "average": 0.988256, "min": 0.953724}, "location": {"width": 128, "top": 1546, "height": 22, "left": 312}, "words": "No:20100128"}, {"probability": {"variance": 0.000595, "average": 0.98329, "min": 0.930502}, "location": {"width": 111, "top": 1538, "height": 22, "left": 582}, "words": "第10页共11页"}], "language": 3}